SOUTH SAN FRANCISCO, Calif., May 29, 2013 (GLOBE NEWSWIRE) -- Hyperion Therapeutics (Nasdaq:HPTX) announced today that the company is scheduled to present at the Jefferies 2013 Global Healthcare Conference on Wednesday, June 5 at 4:30 p.m. ET.
Jeffrey S. Farrow, Chief Financial Officer will provide a company overview. To access the live webcast and subsequent archived recording, please visit Hyperion's website at http://investors.hyperiontx.com/events.cfm .
About Hyperion TherapeuticsHyperion Therapeutics, Inc. is a commercial stage biopharmaceutical company committed to developing and delivering life-changing treatments for orphan diseases and hepatology. The company's first commercial product, Ravicti™(glycerol phenylbutyrate) Oral Liquid, was approved in February 2013 and is currently being marketed in the United States. For more information, please visit www.hyperiontx.com .
CONTACT: Sylvia Wheeler, Investor Relations (650) 794-7834 firstname.lastname@example.org
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts